Humacyte
HUMA
161 hedge funds and large institutions have $57.1M invested in Humacyte in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 33 closing their positions.
155% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $765K
59% more capital invested
Capital invested by funds: $35.9M → $57.1M (+$21.3M)
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
12% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 33
1.47% more ownership
Funds ownership: 31.53% → 32.99% (+1.5%)
1% more funds holding
Funds holding: 159 → 161 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.58M |
| 2 |
DKCM
Davidson Kempner Capital Management
New York
|
+$4.63M |
| 3 |
AP
Antipodes Partners
Royal Exchange,
Australia
|
+$4.06M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$2.73M |
| 5 |
Millennium Management
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.93M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.04M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.39M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.36M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$787K |
HUMA Hedge Fund Activity: Q2 2026 in Review
161 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2026, worth a combined $57.1M — up 59% from $35.9M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new HUMA positions and 33 closed out — a net gain of 4 holders — while 56 added to existing stakes and 37 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.58M. The largest seller was BlackRock, cutting an estimated $6.93M.
- 161 institutional investors held Humacyte (HUMA) as of Q2 2026, up from 159 in Q1 2026.
- Funds reported $57.1M of Humacyte stock for Q2 2026, up 59% quarter-over-quarter.
- 37 funds opened new Humacyte positions in Q2 2026 and 33 closed out, a net change of +4 holders.
- The largest Humacyte buyer in Q2 2026 was Alyeska Investment Group, an estimated $5.58M added.
- The largest Humacyte seller in Q2 2026 was BlackRock, an estimated $6.93M sold.
Based on aggregated 13F filings for Q2 2026.